menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Understanding Unresectable Stage III NSCLC: A Radiation Oncologist’s Perspective

For the past several decades, the combination of radiation and chemotherapy has been the standard of care for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC).Although the advances in radiation have shown some benefits, additional treatment options are needed for eligible patients.2,3 That’s why this live broadcast features radiation oncologist Dr Roy Decker, who shares data on a treatment option for unresectable Stage III NSCLC.

References:

  1. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicans evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e314s-e340S.
  2. Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer. KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-2666.
  3. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698-1704.

Sponsored by:   

©2021 AstraZeneca. All rights reserved. US-58430 Last Updated 10/21 

Episodes 1-2 of 2

Schedule27 Nov 2021
Webpack App